{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:14:11Z","timestamp":1789910051861,"version":"4.0.1"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 AI123036-01"],"award-info":[{"award-number":["P01 AI123036-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>Tuberculosis is the ninth-leading cause of death worldwide. Treatment success is approximately 80% for susceptible strains and decreases to 30% for extensively resistant strains.<\/jats:p>","DOI":"10.1128\/aac.00856-18","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T12:51:17Z","timestamp":1528203077000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an<i>In Vitro<\/i>Assay"],"prefix":"10.1128","volume":"62","author":[{"given":"Carolina","family":"de Miranda Silva","sequence":"first","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Hajihosseini","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Myrick","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Nole","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Louie","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Global tuberculosis report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Chapter 3, TB disease burden, p 21\u201362. Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/, Accessed 23 March 2018."},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. 2017. Chapter 4 Diagnosis and treatment: TB HIV-associated TB and drug-resistant TB p 63\u201396. Global tuberculosis report 2017. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 23 March 2018."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101311"},{"key":"e_1_3_2_5_2","first-page":"273","article-title":"The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS","volume":"31","author":"Selkon JB","year":"1964","unstructured":"Selkon JB, Devadatta S, Kullarna KG, Mitchinson DA, Narayana AS, Nair CN, Ramachandran K. 1964. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ 31:273\u2013294.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00139-10"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407426"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02410-14"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M803899200"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_3_2_11_2","volume-title":"NDA 204384","author":"Food and Drug Administration, Center for Drug Evaluation and Research","year":"2012","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. 2012. NDA 204384. Food and Drug Administration, Silver Spring, MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/204384Orig1s000ltr.pdf. Accessed 17 April 2018."},{"key":"e_1_3_2_12_2","volume-title":"Assessment report 329898\/2013","author":"European Medicines Agency Committee for Medicinal Products for Human Use","year":"2013","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. 2013. Assessment report 329898\/2013. European Medicines Agency, London, UK. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002614\/WC500163215.pdf. Accessed 17 April 2018."},{"key":"e_1_3_2_13_2","volume-title":"NDA 21-130, 21-131, 21-132","author":"Food and Drug Administration, Center for Drug Evaluation and Research","year":"2000","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. 2000. NDA 21-130, 21-131, 21-132. Food and Drug Administration, Silver Spring, MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021130s022lbl.pdf. Accessed 17 April 2018."},{"key":"e_1_3_2_14_2","volume-title":"A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis","author":"National Institutes of Health, National Library of Medicine","year":"2015","unstructured":"National Institutes of Health, National Library of Medicine. 2015. Clinical trial identifier NCT02333799. A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis. National Library of Medicine, Bethesda, MD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02333799. Accessed April 17 2018."},{"key":"e_1_3_2_15_2","volume-title":"An open-label RCT to evaluate a new treatment regimen for patients with multi-drug resistant tuberculosis (NEXT)","author":"National Institutes of Health, National Library of Medicine","year":"2015","unstructured":"National Institutes of Health, National Library of Medicine. 2015. Clinical trial identifier NCT02454205. An open-label RCT to evaluate a new treatment regimen for patients with multi-drug resistant tuberculosis (NEXT). National Library of Medicine, Bethesda, MD. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02454205. Accessed April 17 2018."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3251"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio884"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco WR","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331\u2013385.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2153"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1655-1659.2000"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1051-1058.2000"},{"key":"e_1_3_2_22_2","volume-title":"ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"D'Argenio DZ","year":"2009","unstructured":"D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06383-11"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3791\/56375"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00821-10"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00149.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S407"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1994.1586"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.32.22747"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01125-12"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00856-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00856-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:15Z","timestamp":1751673615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00856-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1128\/AAC.00856-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00856-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"2018-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00856-18"}}